As the pharmaceutical industry enters 2026, manufacturing leaders face a complex landscape shaped by geopolitical uncertainty, capacity constraints, and evolving therapeutic modalities. We asked senior executives across the sector what they see ahead—and their predictions reveal an industry bracing for
Kyriakos Kansos and George Ntortas of Fuliginous Management Consulting identify the trends that will define biopharma outsourcing over the next 12 months. In 2026 there are four forces are set to reshape the CDMO outsourcing landscape. 1. Modalities Face Capacity-Demand
Book your ticket DOWNLOAD The CDMO Live Report 2025 Download our essential 50-page report, bursting with insights from Europe’s most electric external manufacturing event at Rotterdam’s World Trade Center. CDMO Live Report 2025 is a comprehensive 50-page document that captures
Novo Nordisk received FDA approval Monday (22nd December) for oral Wegovy (semaglutide), marking the first oral GLP-1 receptor agonist cleared for obesity treatment. The Danish drugmaker plans a full US launch in early January 2026, with manufacturing underway at its
“When I walked into the tech transfer, we were a million dollars over budget, six months behind schedule, and struggling to make a single successful batch,” says Amy Gamber. Amy Gamber, Executive Director, Lifecycle Lead at Kyverna Therapeutics, specializes in
Watch the presentation of the results with MasterControl
On November 21st 2025 Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation this week, worth more than twice the value of any other drugmaker. The company’s stock has soared on the back of the
“We are not in a transient moment – this will affect industry profitability for decades. The previous era of rule-based international trade is gone” Frank Binder, Managing Director at GSCA (Global Supply Chain Advisors) and former Head of Supply Chain
“We became an analytical powerhouse before we started offering integrated process development and manufacturing. That’s what differentiates us.” Sigma Mostafa, Chief Scientific Officer, and Katie Edgar, Chief Business Officer at KBI Biopharma, explain how technical depth in analytics and proprietary
Ascend Advanced Therapies has released new data showing that two proprietary manufacturing enhancers deliver a substantial increase in adeno-associated virus (AAV) production yields without affecting product quality. The enhancers were tested across multiple scales in HEK293 cells using both Ascend’s EpyQ®
